Treatment of Extended Spectrum Betalactamase Producing Bacteria Causing Urinary Tract Infections in General Practice

What is the Outcome of Treatment of Urinary Tract Infections Caused by Bacteria Producing Extended Spectrum Betalactamase in a Primary Care Setting?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01531023

Enrollment

168

Registered

2012-02-10

Start date

2013-04-30

Completion date

2016-09-30

Last updated

2016-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Tract Infections

Keywords

Extended-Spectrum Beta-lactamase Producing Bacteria

Brief summary

The prevalence of extended spectrum beta-lactamase (ESBL) producing bacteria found in urine sample cultures has been increasing over the past decades. The study hypothesis is to assess the clinical and microbiological outcome of pivmecillinam treatment of ESBL producing E. coli and K. Pneumoni, as well as to observe the clinical and microbiological outcome of the same group of bacteria treated with other antiinfectious agents. Samples are gathered in primary care setting.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Healthy volunteers

Inclusion criteria

\- All patients were urinary sample taken in a primary care setting shows significant growth of ESBL producing E. coli. Above age 16.

Exclusion criteria

\- Sample from patients in hospital care or living in nursing home facilities. Inability to understand and sign information leaflet.

Design outcomes

Primary

Measure	Time frame	Description
Number of days until symptomatic resolution	Two weeks after finishing the primary antibiotic treatment	Number of days from the start of treatment that the patient feels completely free of urinary tract symptoms Number of days after start of antibiotic treatment with mecillinam when the patient feels free of symptoms from the urinary tract

Secondary

Measure	Time frame	Description
Number of patients with ESBL producing bacteria detected in a urine sample taken two weeks after finishing initial treatment	Two weeks after end of initial treatment	—
Number of patients who received a second treatment regime in the follow-up period	2 weeks after end of initial treatment	Number of patients who received a secondary antibiotic treatment to obtain clinical cure.

Countries

Norway

Outcome results